NCT07659626招募中不适用
A Randomized, Investigator-masked, Longitudinal Study Evaluating Long-term Changes in Symptoms and Tear Production of Acoltremon Ophthalmic Solution 0.003% Compared to Control in Subjects With Dry Eye Disease
The Eye Care Institute2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年8月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Mean change from baseline in ODS-VAS
研究概览
简要总结
This is a prospective, longitudinal, single-center study designed to evaluate the long-term changes in symptoms and tear production in subjects with dry eye disease. The study is randomized and investigator-masked, with subjects assigned to either the TRYPTYR (Acoltremon ophthalmic solution 0.003%) arm or the control arm (Refresh Classic Preservative-free). The study will be conducted at a single site, with subjects undergoing assessments at baseline and at months 1, 3, 6, 9, and 12.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 18 years of age or older at the Screening visit.
- •Have a previous history of DED, clinician diagnosed, or patient reported, within the previous 6 months prior to the Screening visit.
- •Have used, and/or desired to use artificial tears for DED symptoms within 2 months prior to the Screening visit.
- •Both of the following signs of DED in the same eye:
- •Total corneal fluorescein staining score of >= 2 and <= 10 based on the NEI grading scheme, with no one region scoring > 3 in at least 1 eye.
- •Unanesthetized Schirmer test score >= 2 and < 10 mm/5 min in at least 1 eye.
- •If both eyes qualify, the eye with the lower baseline Schirmer score will be the study eye (If the Schirmer score is the same, the right eye will be the study eye).
- •Symptomatic defined as an ODS-VAS score of >=
- •Corrected visual acuity equal to or better than logMar +0.7 (Snellen equivalent equal to or better than 20/100), as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes.
- •Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •Written informed consent from the subject has been obtained prior to any study related procedures.
- •Able, as assessed by the investigator, and willing to follow study instructions and likely to complete all required study visits.
排除标准
- •History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, interfere with the interpretation of the study results or subject safety.
- •Diagnosis of recurrent, ongoing, or active ocular infection.
- •History of ocular surgery within 1 year prior to the Screening visit.
- •Have had a corneal transplant in either or both eyes.
- •Use of contact lenses within 2 hours of any study visit.
- •Use of lid heating therapy or Meibomian gland probing/therapeutic expression within 1 year prior to the Screening visit.
- •Use of artificial tears within 24 hours of Screening visit.
- •Use of any topical ocular anti-inflammatory medication or dry eye pharmaceuticals within 30 days prior to the Screening visit.
- •Use of any topical ocular glaucoma medication within 30 days prior to the Screening visit.
- •Change in use of any other topical ocular medication within 14 days prior to the Screening visit.
- •Use of medications for the treatment of severe DED and/or Meibomian gland disease within 30 days prior to the Screening visit.
- •Initiation, discontinuation, or change in dose of a systemic medication known to cause ocular drying less than 14 days prior to the Screening visit.
- •Use of a systemic corticosteroid less than 30 days prior to the Screening visit.
- •Use of a systemic immunomodulator within 30 days prior to the Screening visit.
- •Use of an investigational product or device within 30 days prior to the Screening visit.
- •At the Screening visit, have uncontrolled or severe systemic allergy, rhinitis or sinusitis.
- •History or presence of significant systemic disease.
- •Known allergies or sensitivity to the study interventions or study diagnostic agents.
- •Women of childbearing potential who are not using a medically acceptable form of birth control.
- •The subject has a condition or is in a situation that, in the Investigator's opinion, may put the subject at significant risk.
研究组 & 干预措施
Control
Refresh Classic Preservative free
干预措施: Refresh classic preservative free (Drug)
Acoltremon 0.003%
干预措施: Acoltremon 0.003% (Drug)
结局指标
主要结局
Mean change from baseline in ODS-VAS
时间窗: 12 months post-treatment initiation
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
Study to evaluate effects of Alpha Keto Analogues of essential amino acids in patients with hepatic encephalopathyCTRI/2025/08/093068Dr Vinay Kumar50
招募中
不适用
Clinical Investigation to Observe the Long-term Safety and Efficacy of the Digital Medical Device 'BELL-001' in Patients Diagnosed With InsomniaInsomniaNCT07582809BELL Therapeutics Inc.40
尚未招募
不适用
Pilot Study to Evaluate Efficacy and Safety of Switching to BIC/FTC/TAF in PWH With a Previous Virological Failure Under CAB/RPV LAINCT07620652Cristina Mussini30
尚未招募
不适用
Altius Peripheral Nerve Stimulation in Amputees After TMR/RPNILower Extremity AmputationPain, Persistent PostsurgicalNCT07571239NYU Langone Health32
招募中
不适用
A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)Spinal Muscle AtrophyNCT07531719Hoffmann-La Roche30